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Abstract  40 
Objective 41 
The Scottish Patient Safety Programme  W Pharmacy in Primary Care collaborative is a quality 42 
improvement initiative adopting the Institute of Healthcare Improvement Breakthrough Series 43 
collaborative approach. The programme developed and piloted High Risk Medicine (HRM) Care 44 
Bundles (CB), focused on warfarin and non-steroidal anti-inflammatories (NSAIDs), within 27 45 
community pharmacies over 4 NHS Regions. Each CB involves clinical assessment and patient 46 
education, although the CB content varies between regions. To support national implementation, 47 
this study aims to understand how the pilot pharmacies integrated the HRM CBs into routine 48 
practice to inform the development of a generic HRM CB process map. 49 
Methods 50 
Regional process maps were developed in 4 pharmacies through simulation of the CB process, staff 51 
interviews and documentation of resources. Commonalities were collated to develop a process map 52 
for each HRM, which were used to explore variation at a national event. A single, generic process 53 
map was developed which underwent validation by case study testing. 54 
Results 55 
The findings allowed development of a generic process map applicable to warfarin and NSAID CB 56 
implementation.  Five steps were identified as required for successful CB delivery: patient 57 
identification; clinical assessment; pharmacy CB prompt; CB delivery; and documentation. The 58 
generic HRM CB process map encompasses the staff and patients' journey and ƚŚĞ ?Ɛ integration 59 
into routine community pharmacy practice. Pharmacist involvement was required only for clinical 60 
assessment, indicating suitability for whole-team involvement. 61 
Conclusions 62 
Understanding CB integration into routine practice has positive implications for successful 63 
implementation.  The generic process map can be used to develop targeted resources, and/or be 64 
disseminated to facilitate CB delivery and foster whole team involvement.  Similar methods could be 65 
utilised within other settings, to allow those developing novel services to distil the key processes and 66 
consider their integration within routine workflows to effect maximal, efficient implementation and 67 
benefit to patient care. 68 
Key words 69 
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Introduction   73 
Studies within the United Kingdom (UK) show 6.5% of hospital admissions are attributed to adverse 74 
effects of High Risk Medicines (HRM) - including Warfarin and Non-steroidal anti-inflammatory drugs 75 
(NSAIDs).1 This figure is not dissimilar to international prospective studies and similar causative 76 
medicines have been identified as high risk.2, 3 The pharmacist ?Ɛ potential contribution to patient 77 
safety within primary care has been highlighted,4 ĂŶĚŝŶƚĞƌŶĂƚŝŽŶĂůůǇĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?ƌŽůĞƐ78 
are expanding to be increasingly integrated within primary care.5-7  79 
Within the UK, this transition has resulted in the introduction of new services including community 80 
pharmacy minor ailment schemes, with positive feedback from pharmacists and patients.8-10 The 81 
drive for community pharmacy to provide enhanced patient safety services aligns with the Scottish 82 
Government ?s vision and action plan, Prescription for Excellence.6 Within Scotland, a national patient 83 
safety programme has since launched within community pharmacy in 2014, called The Scottish 84 
Patient Safety Programme - Pharmacy in Primary Care (SPSP-PPC) collaborative.11 85 
The SPSP-PPC collaborative is a multi-site quality improvement initiative adopting the Institute of 86 
Healthcare Improvement Breakthrough Series collaborative approach - a structured learning model 87 
consisting of Learning Sessions to share progress and discuss practice changes and Action Periods 88 
where those changes are tested in the health care setting.12 Participating pharmacy teams were 89 
trained in the Model for Improvement which was the guiding quality improvement framework 90 
operationalised at pharmacy site level through the appliĐĂƚŝŽŶŽĨ ‘WůĂŶ-Do-Study-Đƚ ? ?W^ ?cycles, 91 
as a means to facilitate rapid testing of small-scale changes.13  92 
The programme aims to improve patient safety by implementing safety interventions using a team-93 
based approach. An ambition of the programme is to make community pharmacy processes safer 94 
while strengthening their contribution within primary care. A core component was to reduce the risk 95 
associated with the HRMs Warfarin and NSAIDs through the development of Care Bundles (CBs), 96 
ĚĞĨŝŶĞĚĂƐĂ “structured way of improving the processes of care and patient outcomes: a small, 97 
straightforward set of evidence-based practices ? ?14 Box 1 provides an overview of the programme 98 
structure and the HRM CBs developed.   99 
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Box 1. Overview of the Programme Structure and the High Risk Medicine Care Bundles  100 
Programme Structure and Leadership:  
x Four NHS Regions were recruited, involving 27 pharmacy sites in total  
ම ZĞŐŝŽŶ ? ?ŶA? ? ?මZĞŐŝŽŶ ? ?ŶA? ? ? 
ම ZĞŐŝŽŶ ? ?ŶA? ? ?මZĞŐŝŽŶ ? ?ŶA? ? ? ? 
x National Leads (n=2), Regional Leads (n=8), Programme Officers, Data Analysts, 
Improvement Advisors and the Evaluation Team comprise the SPSP-PPC Steering Group. 
Programme Support: 
x Two National Learning Events (NLE) and 2 Local Learning Events (LLE) were attended by 
teams from each pharmacy site, typically comprising a pharmacist and a member of 
ƐƵƉƉŽƌƚƐƚĂĨĨ ?ƚŚĞ “ǁĂǇdĞĂŵ ? ? ?ŽŶĐĞƉƚƐŽĨƉĂƚŝĞŶƚƐĂĨĞƚǇ ?ƐĂĨĞƚǇĐƵůƚƵƌĞĂŶĚYƵĂůŝƚǇ
Improvement methods were taught and the HRM CBs introduced.  
x Regional Leads provided local support, and pharmacy resources developed included an 
SPSP Launch Folder and the SPSP-PPC Knowledge Network website. 15 
HRM CBs: 
x Region-specific CBs comprising of 4-6 questions relating to a measure of care were 
developed by the Regional Leads and pharmacy Away Teams using driver diagrams.  
x The NSAID CB measures focused on concordance, assessment of side effects, gastro-
protection and co-prescribing of other high-risk medications.  
x dŚĞtĂƌĨĂƌŝŶŵĞĂƐƵƌĞƐĨŽĐƵƐĞĚŽŶƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞŽĨŝŶƚĞƌĂĐƚŝŽŶƐĂŶĚƐŝĚĞ
ĞĨĨĞĐƚƐ ?ĂŶĚƉĂƚŝĞŶƚƐ ?ƵƐĞŽĨƚŚĞ warfarin record book and alert card. 
x Pharmacy staff compliance with CB measures were documented on run charts, to allow 
ǀŝƐƵĂůƌĞƉƌĞƐĞŶƚĂƚŝŽŶŽĨƉŚĂƌŵĂĐǇƐŝƚĞƐ ?ŝŵƉƌŽǀĞŵĞŶƚĂŶĚƚŚĞŝŵƉĂĐƚŽĨW^ĐǇĐůĞƐ ? 
 101 
An anticipated challenge to the adoption of new services within pharmacy practice is the potential 102 
variation of processes, as it is well established that integration within existing workflow can 103 
influence successful implementation of health service innovations.16-18 Variation in pharmacy 104 
practice has been identified within other health services, 19-21 although to our knowledge there has 105 
been no research into the extent of process variation within the Scottish community pharmacy 106 
setting. Consequently, an understanding of this variation may support national implementation of 107 
the HRM CB by allowing consideration of how this novel service could successfully integrate into 108 
routine pharmacy practice. 109 
This study aims to understand how the pilot pharmacies integrated the novel HRM CBs into routine 110 
practice in order to inform the development of a generic process map that could be used to facilitate 111 
national implementation.  112 
Methods  113 
A qualitative case-study method was employed.22 Process mapping was applied throughout the 114 
study. This involves exploration of the tasks occurring within a process, with the findings used to 115 
develop sequential flow charts of the actions and decisions performed, with arrows depicting the 116 
sequence of activities.23 Due to the complexity of the programme design  W with a focus on 2 117 
different HRMs and 4 different care bundles operationalized in different regions  W a four-phased 118 
approach was used. An overview of the methods is shown in Figure 1.  119 
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Figure 1. Staged Process Map Development 120 
 121 
Phase 1: Development of Regional Process Maps 122 
Pharmacies were selected for case study on-site evaluations based on March 2015 activity data 123 
reporting on number of patients delivered the CB, CB compliance and reliability. The top 3 124 
performing pharmacies within each NHS Region were identified, and final selection agreed in 125 
discussion with the Regional Leads taking account of feasibility of on-site visits. One pharmacy from 126 
each participating NHS Region was chosen and contacted to arrange suitable dates. 127 
During June and July 2015 case studies were conducted. Data were collected in 3 ways: (1) 128 
observation of a simulation of the CB process with pharmacy staff, (2) documentation of resources 129 
used and (3) staff interviews. Demographic details of participants collected included gender, job role 130 
and duration worked in community pharmacy.  131 
The simulation exercise involved pharmacy staff providing Ă “ƚĂůŬĂŶĚǁĂůŬƚŚƌŽƵŐŚ ?ŽĨƚŚĞCB 132 
process as it would normally be delivered to a patient.24 This allowed for resources used within the 133 
pharmacy environment to act as material probes to prompt discussion, and was thought to allow for 134 
better understanding of the workflow than with traditional interviews.25 Photographs of relevant 135 
pharmacy resources were taken with permission, and identifiable information anonymised. Semi-136 
structured interviews with pharmacy staff were guided by a pre-designed interview schedule 137 
(Appendix 1). The Away Team participants were interviewed, followed by a convenience sample of 138 
the remainder of the pharmacy staff. Both the simulation exercise and interviews were audio-139 
recorded. The interviews were transcribed using an intelligent verbatim approach and were 140 
anonymised to protect participant identity. The resultant data were used to develop a process map 141 
for each of the 4 NHS Regions.  142 
Phase 2: Development of Warfarin and NSAID Process Maps 143 
A process map for each HRM (warfarin and NSAIDs) was developed using Lucidchart software.26 This 144 
involved visually inspecting the regional process maps to distil commonalities and differences 145 
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between the sites. This was supported by re-visiting the original audio recordings and documented 146 
resources.  147 
Phase 3: Development of a Generic HRM Process Map   148 
To develop a single HRM generic process map, pharmacy staff who attended the National Learning 149 
Event (NLE) in November 2015 completed an exercise to assimilate variation in processes between 150 
sites. Each Pharmacy Team received a copy of the NSAID or Warfarin Process Map depending on 151 
their NHS Region. Steps that were not commonalities were included within each HRM process map 152 
to allow participants to comment on. A paper-based variation exercise (Appendix 2) was provided 153 
and participants were instructed to provide written comments on the differences between the 154 
process maps presented and the processes within their pharmacies.   155 
All responses were transcribed using an intelligent verbatim approach, and were coded using NVivo 156 
v.10. Initially, inductive content analysis was employed, followed by a deductive process of aligning 157 
the codes to the process steps identified within the HRM process maps.27 To allow for comparative 158 
analysis of variation, responses were classified according to NHS Region and HRM. Examination of 159 
the commonalities between processes was used to create a generic HRM process map detailing the 160 
core steps fundamental to successful delivery of the CBs.  161 
Phase 4: Validation  162 
The generic HRM process map was validated against regional process maps developed from a 163 
further 4 case studies conducted during October 2015.  These involved either on-site or telephone 164 
data collection (for Region 1 and 3 due to rural location). To maximise variability, the selection 165 
process identified the lower performing pharmacies based on March 2015 reliability data and the 166 
final decision informed primarily by discussion with the NHS Regional Leads on feasibility of on-site 167 
visits. 168 
The same simulation exercise method was applied as before, however for the telephone interviews a 169 
verbal explanation of the CB process was recorded and participants were asked to email 170 
photographs of any resources used.28 171 
The regional process maps developed were compared with the generic HRM process map. Three 172 
aspects were considered during the validation: if each site had a process for the core steps, if there 173 
were other steps identified, and what order the steps occurred.  174 
Informed consent was gained throughout. Under UK research governance arrangements, ethical 175 
approval was not necessary as this was a service evaluation of a quality improvement programme.29 176 
Results  177 
Participants  178 
Of the 27 community pharmacies participating in the SPSP-PPC pilot, 8 pharmacies participated in 179 
case studies, representing 30% of all sites. Pharmacy site demographics are shown in Table 1.  180 
  181 
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Table 1. Pharmacy site demographics 182 
Pharmacy site demographics 
 
All sites 
 (n=27) 
Phase 1 case 
studies (n=4) 
Validation case 
studies (n=4) 
Pharmacy type* N, (%) N, (%) N, (%) 
   Single, independent pharmacy 7 (26%) 1 (25%) 1 (25%) 
   Small chain  2 (8%) 1 (25%) 0 (0%) 
   Medium chain  5 (19%) 2 (50%) 1 (25%) 
   Large chain  13 (48%) 0 (0%) 2 (50%) 
Location  N, (%) N, (%) N, (%) 
   Urban 21 (78%) 3 (75%) 3 (75%) 
   Rural 6 (22%) 1 (25%) 1 (25%) 
Range of pharmacy staff numbers Ώ 3-18 5-18 4-11 
*Small chain defined as 2-4 pharmacies, Medium chain defined as 5-30 pharmacies, Large chain 183 
defined as >30 pharmacies 184 
 ?Pharmacy staff numbers were determined retrospectively by telephoning participating pharmacies 185 
and asking them to provide a best estimate of number of pharmacy staff.   186 
Nineteen staff members participated in the Phase One case studies (4-5 from each site). Of which, 187 
84% were female (n=16), 37% were pharmacists (n=7) and the remainder were support staff. Most 188 
(74%, n=14) had 10 years or less experience in community pharmacy. For the validation case studies, 189 
it was the on-site pharmacist who participated in the simulation exercise.  190 
At the time of the NLE variation exercise (Phase 3), one of the pharmacies involved in the phase one 191 
case studies withdrew participation. Of the remaining 26 pharmacy sites, all had Away Team 192 
representatives who participated in the variation exercise. Forty-one people participated in the 193 
variation exercise, participants were mostly female (n=28, 68%), pharmacists or pre-registration 194 
pharmacists (n=29, 71%), and most had over 10 ǇĞĂƌƐ ?ĞǆƉĞƌŝĞŶĐĞŝŶĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐǇ ?ŶA? ? ? ?195 
52%). Full demographics of pharmacy staff participants are shown in Supplementary File 1.  196 
Pharmacy Workflow and CB Core Steps 197 
From Phase One it was apparent that each pharmacy had similar dispensary workflow comprising: 198 
(1) prescription received by a member of pharmacy staff; (2) prescription details inputted into the 199 
Patient Medical Record (3) medicines assembled including generating labels; (4) clinical and accuracy 200 
check; (5) medicines prepared for collection; (6) medicine supplied to patient; and (7) patient 201 
counselling, if appropriate.  202 
To synthesise the regional process maps to a single Warfarin and single NSAID process map (Phase 203 
2), three areas of importance were identified: work processes, staff involvement and resources. This 204 
is shown in Supplementary File 2. Responses to the variation exercise (Phase 3) where the Warfarin 205 
and NSAID process maps were presented to participants, revealed that despite differing local 206 
practices (i.e. variable resources used), there were 5 core steps surrounding CB delivery which 207 
integrated within each pharmacies local dispensing process, described in Table 2.  208 
  209 
8 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Table 2. Description of Core Steps involved in CB Delivery  210 
 211 
(1) Patient 
Identification 
Identification of patients on an HRM (either Warfarin or an NSAID) and 
eligible to be delivered the CB, either via the presentation of an HRM 
prescription or via the electronic Patient Medication Record system. 
(2) Clinical 
Assessment 
Clinical assessment of the HRM performed by the pharmacist (e.g. 
medication suitability, interactions, and contraindications). 
(3) Pharmacy CB 
Prompt 
Highlighting during the dispensing process that a patient is to be delivered 
the CB (i.e. by using alert stickers) to alert the pharmacy team and act as a 
prompt to deliver the CB. 
(4) CB Delivery Delivering the CB to the patient, for example when they present to the 
pharmacy to collect their prescription or by a telephone consultation.  
(5) Documentation Documentation that the CB was delivered, although variable systems were 
adopted within the pharmacy sites.  
 212 
During the variation exercise, some participants offered their opinion of the NSAID and warfarin 213 
process maps as a resource.  dŚĞƉƌĞƐĞŶƚĂƚŝŽŶǁĂƐĐŽŵŵĞŶƚĞĚƚŽďĞĂ “ĐůĞĂƌĂŶĚůŽŐŝĐĂů ?214 
ƌĞƉƌĞƐĞŶƚĂƚŝŽŶŽĨƚŚĞƉƌŽĐĞƐƐ ?ĂŶĚƚŚĂƚ “ĂůůŝŶĨŽƌŵĂƚŝŽŶǁĂƐĐŽŶƚĂŝŶĞĚŝŶŽŶĞƉůĂĐĞ ? ?Participants 215 
mentioned iƚƐĞĂƐĞŽĨƵƐĞ ? “ŝƚŝƐĞĂƐǇƚŽĨŽůůŽǁǁŽƌŬĨůŽǁĐŚĂƌƚ ? ?ĂŶĚƚŚĂƚŝƚĐŽƵůĚprompt staff of the 216 
required steps. However, 3 participating pharmacies felt the process map was too complex. Also 217 
unprompted, 4 participants said that provision of a process map could facilitate staff involvement. 218 
 “Process map - Biggest advantage will be to get other people involved. Even on your days off 219 
everybody can carry on with the care bundle ? ?(Pharmacy site 4, NSAID CB, large chain 220 
pharmacy) 221 
Integration of the CB  222 
The commonalities between the NSAID and Warfarin CB processes and how it integrated into 223 
practice were sufficient to allow a generic process map to be developed, where it is evident that 224 
pharmacist involvement is required only for the clinical assessment stage. The HRM CB generic 225 
process map developed is shown in Figure 2.  226 
Validation of the Generic HRM Process Map 227 
The generic HRM process map validation (Phase 4) revealed that all sites had a process for each of 228 
the 5 core steps, no additional steps were identified, and the order of the steps was comparable.  229 
Within one pharmacy there was a two-step patient identification process involving both the support 230 
staff and pharmacist. A member of support staff would see an electronic prompt indicating eligibility 231 
during the dispensing process (i.e. that the patient was prescribed a HRM) and would gather 232 
appropriate resources. This prompt did not indicate if the CB had previously been delivered to the 233 
patient. The pharmacist subsequently checked if the patient had previously been delivered the CB; if 234 
yes, it would not be repeated. As this two-step process was not reflective of the majority of sites 235 
process the generic process map was not altered.  236 
  237 
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Figure 2. High Risk Medicine Care Bundle Generic Process Map  238 
 239 
 240 
Discussion 241 
The study details how the SPSP-PPC pharmacies integrated the CBs into their working practice. 242 
Through the exploration of variation, this study identified 5 core steps fundamental to the delivery 243 
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of the CBs and suitability for a whole team approach - depicted through a generic process map. The 244 
sites followed a similar sequential process, encompassing the core steps, adopted individually to fit 245 
within their working systems. Despite the heterogeneity of the participating pharmacies, sufficient 246 
commonalities enabled development of a generic HRM process map to assist national 247 
implementation.  248 
Strengths and Limitations 249 
The phased development of the generic process map allowed all participating pharmacies to 250 
contribute. We believe this method reduced the effects of any bias within the data gathered, 251 
however, as with any simulation exercise the Hawthorn effect is an unavoidable bias which may 252 
ŚĂǀĞŝŶĨůƵĞŶĐĞĚƚŚĞĚĂƚĂŐĂƚŚĞƌĞĚǀŝĂƚŚĞ “ƚĂůŬĂŶĚǁĂůŬƚŚƌŽƵŐŚ ?ƐŝŵƵůĂƚŝŽŶŵĞƚŚŽĚ ?30 Additionally, 253 
during the on-site simulation exercise there was a tendency for the pharmacist to lead this 254 
discussion, although the NLE variation exercise sought input from both pharmacists and support 255 
staff participants. 256 
The commonalities with the 5 core stages observed between the pharmacies suggest that our 257 
conclusions have validity and are generalisabile. The heterogeneity of the current sample adds 258 
confidence regarding the relevance of the process map nationally. However, the authors appreciate 259 
that transferability of findings to all community pharmacies (n= 1,253) in Scotland cannot be 260 
assumed, in part due to the heterogeneity of pharmacy characteristics within the UK, such as 261 
ownership and size diversity.31 Therefore, the generic process map was intentionally designed to be 262 
sufficiently high-level to act as a service blueprint,32 which avoids being over-prescriptive and could 263 
accommodate local system adoption on a larger scale. This would allow people to adopt a two-step 264 
patient identification process, as observed within one of the latter case studies, if they wished. 265 
Unlike traditional methods of process mapping which focus on identifying system faults, this study 266 
ĂƉƉůŝĞĚƉƌŽĐĞƐƐŵĂƉƉŝŶŐĂƐĂ “ďŽƚƚŽŵƵƉ ?ĂƉƉƌŽĂĐŚƚŽƵŶĚĞƌƐƚĂŶĚǀĂƌŝĂƚŝŽŶĂŶĚŝŶƚĞŐƌĂƚŝŽŶŽĨƚŚĞ267 
CBs.33 It is acknowledged that other methods of exploring work process variation exist, such as 268 
human factors models which aim to understand the complex interactions between people, tasks, 269 
technology and the wider environment they work within and how these influence overall system 270 
performance and human wellbeing.34, 35 However, this requires significant expertise and effort, while 271 
process mapping was selected purposefully as its application within improvement and safety 272 
initiatives is well established and feasible.33, 36  273 
Implications 274 
The methodology applied has allowed understanding of how the CB process integrated into routine 275 
practice.  Understanding integration of novel innovations into practice is an important consideration 276 
of both local and international significance. Within Scotland, evaluation of a national platform, the 277 
Pharmacy Care Record system, suggested a lack of integration into practice when only 13.7% of 278 
pharmacists used the system daily.37 For quality-related initiatives in Canada, integration into 279 
community pharmacy practice was identified as one of six supporting factors,38 and incompatibility 280 
with the layout and workflow of the pharmacy was a cited barrier to the provision of written 281 
medicine information to patients in an Australian study.39  The authors propose that further 282 
application of the methodological approach outlined in this study within community pharmacy could 283 
mitigate barriers for future innovations, especially considering the drive for community pharmacies 284 
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to offer more clinical services. This could become of greater importance as the emergence of 285 
eHealth technology, such as automatic dispensing and electronic prescribing, may challenge and 286 
reshape traditional workflows.34, 40-43 287 
Furthermore, the development of the generic process map may allow senior leaders to visualise the 288 
process in practice and thus facilitate strategic decision making when considering the national 289 
implementation of the CBs. The identification of the CB core stages allows for the targeted 290 
development of resources and offers understanding to the degree of facilitation required for 291 
national implementation. For example, the findings of this study highlighted that variable 292 
documentation methods were adopted by the pilot pharmacies, and consequently national 293 
implementation may be facilitated by an update of the eHealth system already available nationally 294 
within Scottish community pharmacies.44 295 
The generic HRM process map highlights the scope for whole team involvement with the HRM CBs, 296 
which was an unexpected but positive finding. Within the UK, a potential link has been identified 297 
between the involvement of support staff and pharmacy engagement with public health 298 
initiatives,45, 46 and internationally the potential benefits of support staff involvement has been 299 
recognised. Reviews of community pharmacy services in the United States found involvement of 300 
ƚĞĐŚŶŝĐŝĂŶƐŝŶǁŽƌŬƚŚĂƚĚŽĞƐŶŽƚƌĞƋƵŝƌĞƉƌŽĨĞƐƐŝŽŶĂůũƵĚŐĞŵĞŶƚůĞƐƐĞŶƐƚŚĞ “ĚŝƐƉĞŶƐŝŶŐďƵƌĚĞŶ ?301 
and helps overcome time constraints.47, 48 In New Zealand, a survey of pharmacists and pharmacy 302 
technicians revealed support for technicians adoption of more advanced roles,49, 50 and Australian 303 
community pharmacists and strategists consideƌĞĚƚĂƐŬĚĞůĞŐĂƚŝŽŶĂƐ “ĞƐƐĞŶƚŝĂů ?ĨŽƌƐƵĐĐĞƐƐĨƵů304 
implementation of clinical pharmacy services.51  305 
However, results from the wider SPSP-PPC evaluation indicate that although whole team 306 
involvement was possible, in reality, the onus was often on the pharmacist to deliver the CBs.52 307 
Within the UK, although task delegation is reported to be widely employed within community 308 
pharmacies and support staff are considered competent to absorb further roles, barriers to task 309 
delegation exist and include concerns over accountability, with mixed views about the 310 
reconfiguration of the skill mix within community pharmacies.53, 54 As participants within this study 311 
reported positively that the process map could encourage staff involvement, the generic process 312 
map could be disseminated to pharmacies as an operational tool to facilitate implementation by 313 
promoting whole-team engagement and task delegation. The use of process maps in community 314 
pharmacy has previously been suggested to improve efficiency, identify support staff roles and 315 
ensure higher skilled staff perform tasks only themselves can do,47 echoing some of the participants 316 
comments within this study.  317 
The feasibility of developing a generic process map for the CBs, derived in this study from different 318 
HRM areas, suggests potential adaptability of the process to varying clinical contexts. Scope 319 
therefore lies, once nationally implemented, for the CBs clinical content to be adapted in light of 320 
emerging safety concerns. This could be a promising platform to allow for seamless translation of 321 
evidence into practice and would benefit from further research.  322 
Conclusions 323 
ƐĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝĞƐ ?ĐŽŶƚƌŝďƵƚŝŽŶǁŝƚŚŝŶƚŚĞƉƌŝŵĂƌǇĐĂƌĞŚĞĂůƚŚƐĞĐƚŽƌŝƐŝŶĐƌĞĂƐŝŶŐůǇ324 
recognised, an understanding of how novel services and approaches to healthcare delivery can 325 
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integrate into routine practice is crucial. The methods employed in this study were successful in 326 
determining the core steps involved, and the contribution of resources and staff members. Overall, it 327 
provides an understanding of the extent of variation when considering the adoption of a CB 328 
approach to drive quality improvement in patient care.  Similar methodology may be utilised further 329 
within this, and other settings, to allow those developing novel services to distil the key processes 330 
and consider their integration within routine workflows to effect maximal, efficient implementation 331 
and benefit to patient care.  332 
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 486 
Appendices 487 
Appendix 1. Phase 1 semi-structured interview guide: 488 
1) Are you involved in the warfarin/NSAID programme? 489 
a. If yes, 490 
i. What are you doing? How are you doing it? 491 
ii. What is going really well? 492 
iii. ŚĂůůĞŶŐĞƐĂŶĚŚŽǁǇŽƵ ?ǀĞŽǀĞƌĐŽŵĞƚŚĞŵ 493 
b. /ĨŶŽ ?ƚŚĞŝŶƚĞƌǀŝĞǁĞƌŐŝǀĞďƌŝĞĨĞǆƉůĂŶĂƚŝŽŶŽĨǁŚĂƚ ?ƐďĞŝŶŐĚŽŶĞ 494 
i. How do you think you could be involved 495 
ii. Have you been affected by it in any way? 496 
 497 
2) How disruptive is this evaluation process  W can we do anything differently? 498 
 499 
Appendix 2. Phase 3 variation exercise questions: 500 
Q1: What are the differences between this model and the processes within your site? Can you 501 
explain why this is? 502 
Q2:  Which steps in the process map do you find challenging and how are these overcome? 503 
Q3: What advantages/disadvantages can you see in this approach? Would you consider 504 
reviewing/revising your processes in light of this process map?  505 
  506 
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Supplementary Files 507 
Supplementary File 1. Demographics of pharmacy staff participants  508 
 Phase 1 Case Study Participants  Phase 3 Pharmacy  
Away Team 
Participants (n=41) 
 Region 
1, (n=5)  
Region 
2, (n=4)  
Region 
3, (n=5) 
Region 
4,  (n=5) 
Total 
(n=19) 
Gender   
Male  
Female  
0  
5  
1  
3  
0 
5 
2 
3 
3 
16 
13 
28 
Duration worked in Community Pharmacy (years)   
<1 
1 ʹ 5  
6 ʹ 10  
11 - 15 
16 ʹ 20  
>20 
Unknown 
0 
1  
3  
0 
1  
0 
0  
0 
0  
2  
0 
0  
2  
0 
1 
4 
0 
0 
0 
0 
0 
0 
1 
2 
0 
1 
1 
0 
1 
6 
7 
0 
2 
3 
0 
3 
8 
9 
6 
4 
9 
2 
Job Role*  
Pharmacist 1 2 1 3 7 29 
Support staff 4 2 4 2 12 12 
Pharmacy Away Team demographics collected from NLE registration documentation.  509 
*Pharmacist includes pre-registration pharmacists, which in the UK is a trainee who has completed 510 
 their Masters of Pharmacy undergraduate degree and is participating in a one-year placement prior 511 
to becoming a fully qualified pharmacist. Support staff includes pharmacy technicians, dispensing 512 
assistants and medicine counter assistants.  513 
 514 
  515 
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Supplementary File 2. Local variation between regional processes (Phase 1) 516 
Step Variation Outcome 
Work processes 
Process for delivering the care 
bundle if the patient/carer 
ĚŝĚŶ ?ƚƉƌĞƐĞŶƚƚŚĞŵƐĞůǀĞƐƚŽ
collect the prescription.  
Region 3 and 4 did not stipulate 
a process for this. The other 
regions did which involved 
asking for the patient to attend 
or telephone the pharmacy. 
Deemed important and 
included in both HRM process 
maps. 
This display of an HRM 
educational poster was 
identified as optional. 
Region 4 made a conscious 
decision not to display an 
educational poster as was not 
deemed appropriate. All other 
regions did.  
Included but annotated 
within both HRM process map 
to show optional. 
Consulting Warfarin Record 
Book during care bundle 
delivery.  
Region 1 specifically required 
the warfarin yellow book to 
deliver the care bundle.  
Included but annotated 
within the Warfarin HRM 
process map to show 
optional. 
Process for repeating the care 
bundle to patients. 
 
Region 2 did not repeat the care 
bundle, Region 1 would repeat 
only in the presence of changes. 
Region 3 and 4 did not stipulate 
if the Care Bundle was repeated. 
Included with both HRM 
Process maps to allow others 
at the NLE validation exercise 
to elaborate if repeating to 
patients or not.  
Staff Involvement  
Pharmacy support staff 
involvement was variable 
throughout all four regions 
Involvement included: 
identifying eligible patients, 
delivering the care bundle, 
facilitating enrollment of 
patients who got medication 
delivered and documentation. 
Only HRM clinical assessment 
required pharmacist 
involvement, this was 
annotated within both HRM 
process maps.  
Resources 
Various staff resources used 
throughout all four regions. 
Alert stickers were used to flag 
an HRM prescription to staff 
during dispensing and to 
highlight at point of collection 
that the care bundle should be 
delivered. 
ම NSAID stickers 
ම Speak to Pharmacist stickers 
ම SPSP HRM Stickers  
ම Warfarin Stickers 
ම Warfarin Patient List  
ම ĂƌĞƵŶĚůĞŚĞĐŬůŝƐƚ ? “ŝŶ
ŚŽƵƐĞ ? ?
ම ŶƌŽůůŵĞŶƚƐƚŝĐŬĞƌƐ ? “ŝŶ
ŚŽƵƐĞ ? ?
Staff resources were included 
within the corresponding 
HRM Process map to 
ascertain resources used by 
other staff.  
ZĞƐŽƵƌĐĞƐĐƌĞĂƚĞĚ “ŝŶŚŽƵƐĞ ?
for sole use in that pharmacy 
were not included.  
 
Various Patient resources used 
throughout all four regions. 
ම Warfarin Yellow Book 
ම NSAID Safety Card 
ම Medicines Sick Day Card 
Patient resources were 
included within the 
corresponding HRM process 
map to ascertain resources 
used by other staff.  
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